Akili Builds Medical Team with Newly Appointed Medical Affairs Leader and Formation of Clinical Advisory Committee in Preparation for Commercial Launch
Summary
BOSTON--( BUSINESS WIRE )-- Akili Interactive (“Akili” or “Company"), a leading prescription digital medicine company developing novel treatments for cognitive dysfunction and brain-related conditions, today announced the appointment of Anil S. Jina, M.D., as Senior Vice President and Head of Medical Affairs and the formation of a new Clinical Advisory Committee.The additions build on Akili’s growing medical team as the Company prepares for the future launch of its first digital medicine and drives the aggressive expansion of its pipeline.Dr. Jina will oversee Akili’s medical affairs strategy and pre-launch efforts for the Company’s lead investigational product, AKL-T01, a potential digital treatment for children with ADHD, currently under review with the U.S. Food and Drug Administration (FDA).The newly formed Clinical Advisory Committee is comprised of the following distinguished medical and healthcare professionals who have made significant contributions to advancing their respective fields:Akili is advancing a broad pipeline of programs to treat cognitive deficiency and improve symptoms associated with medical conditions across neurology and psychiatry, including ADHD, MDD, ASD and various inflammatory diseases.